Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 20/20 | 0.63 |
| ▸ | JAK3 | P52333 | 20/20 | 0.63 |
| ▸ | JAK2 | O60674 | 19/20 | 0.63 |
| ▸ | JAK1 | P23458 | 19/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21490574 | 1.00 | TYK2 (0.63) | TYK2JAK3JAK2JAK1 | |
| SCHEMBL21490887 | 0.85 | TYK2 (0.63) | TYK2JAK3JAK2JAK1 | |
| SCHEMBL21490888 | 0.85 | TYK2 (0.63) | TYK2JAK3JAK2JAK1 | |
| SCHEMBL21490824 | 0.85 | JAK2 (0.51) | TYK2JAK3JAK2JAK1 | |
| SCHEMBL21490827 | 0.85 | JAK2 (0.51) | TYK2JAK3JAK2JAK1 | |
| SCHEMBL21490474 | 0.84 | TYK2 (0.67) | TYK2JAK3JAK2JAK1 | |
| SCHEMBL21490634 | 0.84 | TYK2 (0.61) | TYK2JAK3JAK2JAK1 | |
| SCHEMBL21490835 | 0.84 | TYK2 (0.60) | TYK2JAK3JAK2JAK1 | |
| SCHEMBL21490834 | 0.84 | TYK2 (0.60) | TYK2JAK3JAK2JAK1 | |
| SCHEMBL21490478 | 0.83 | JAK3 (0.53) | TYK2JAK3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| EP-3555096-B1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-23 | — | — | EP | disclosed |
| CN-114685505-A | Imidazopyrrolopyridines as JAK family kinase inhibitors | 詹森药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-110312719-B | Imidazopyrrolopyridines as JAK family kinase inhibitors | 詹森药业有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20210206768-A1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-08 | — | — | US | disclosed |
| US-10981911-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-20 | — | — | US | disclosed |
| US-20190322665-A1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JAK1, JAK2, JAK3 | TYK2 7/4885JAK3 3/4885JAK2 2/4885 |
| US-20210206768-A1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JAK1, JAK2, JAK3 | TYK2 7/4885JAK3 3/4885JAK2 2/4885 |
| US-10981911-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JAK1, JAK2, JAK3 | TYK2 7/4885JAK3 3/4885JAK2 2/4885 |
| US-20190322665-A1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JAK1, JAK2, JAK3 | TYK2 7/4885JAK3 3/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.